Vir Biotechnology

$CytomX Therapeutics(CTMX)$ CytomX（CTMX）最近临床出现一例急性肾衰竭死亡病例，应该与患者基线太差有关（患者只有一个肾脏），IDMC建议继续支持入组；
由 CTMX 公司研发的新型ADC probody(CX-2051) 在2025年5月公布的临床中期分析中展现出不错的疗效和良好的安全性。CX-2051是靶向EpCAM的...

$Vir Biotechnology(VIR)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-25-038431  Act: 34  Size: 6 MB 网页链接

$Vir Biotechnology(VIR)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001628280-25-035847  Act: 34  Size: 281 KB 网页链接

$Vir Biotechnology(VIR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-035269  Size: 6 KB 网页链接

$Vir Biotechnology(VIR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001197020-25-000005  Size: 5 KB 网页链接

$Vir Biotechnology(VIR)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001628280-25-038329  Act: 34  Size: 416 KB 网页链接

$Vir Biotechnology(VIR)$ 144 Report of proposed sale of securities Accession Number: 0001628280-25-034990  Act: 33  Size: 4 KB 网页链接

$Vir Biotechnology(VIR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-043567  Size: 5 KB 网页链接

$Vir Biotechnology(VIR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001493152-25-017612  Size: 12 KB 网页链接

$Vir Biotechnology(VIR)$ 144 Report of proposed sale of securities Accession Number: 0001950047-25-005079  Act: 33  Size: 5 KB 网页链接

$Vir Biotechnology(VIR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001493152-25-017300  Size: 12 KB 网页链接

$Vir Biotechnology(VIR)$ 144 Report of proposed sale of securities Accession Number: 0001950047-25-007655  Act: 33  Size: 6 KB 网页链接

$Vir Biotechnology(VIR)$ 144 Report of proposed sale of securities Accession Number: 0001493152-25-016892  Act: 33  Size: 4 KB 网页链接

$Vir Biotechnology(VIR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-037344  Size: 5 KB 网页链接